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Background. Neutropenic patients with cancer may develop several episodes of fever and infection during
chemotherapy-induced myeloaplasia.
Methods. To identify risk factors for secondary infectious episodes among patients who responded to initial
antibiotic therapy, we retrospectively analyzed 2 consecutive, prospective, randomized clinical trials performed by
the International Antimicrobial Therapy Group of the European Organization for Research and Treatment of
Cancer during 1991–1994.
Results. Of 1720 patients with their first episode of febrile neutropenia, 836 responded to the initial antibiotic
regimen and were therefore suitable for our analysis. A secondary infection was observed in 129 (15%) of 836 patients
that occurred at a median of 10 days (range, 1–28 days) after the onset of the primary febrile episode. Factors at
both baseline and day 4 were analyzed. Age of 116 years (odds ratio [OR], 3.46; ), acute leukemia in firstP ! .001
induction (OR, 3.17; ), presence of intravenous line (OR, 1.88; ), severe neutropenia (defined as anP ! .001 Pp .04
absolute granulocyte count of !100 cells/mm3) on day 4 (OR, 2.72; ), and type of documentation of theP ! .001
primary episode (i.e., microbiologically documented cause or unexplained fever; OR, 2.56; ) were found toPp .001
be risk factors for secondary infection. The risk of death was higher among patients who developed a secondary
infectious episode than among those who did not (5.4% vs. 1.4%; ).P ! .01
Conclusions. The clinical parameters described above may help to identify neutropenic patients at risk of
developing secondary infection.
Broad-spectrum antibiotics are always given empirically
for the treatment of patients with cancer who have neu-
tropenia and fever. This practice has led to a marked
reduction of infectious mortality, although it might result
in overuse of antibiotics and in the emergence of drug-
resistant microorganisms [1]. Aggressive antineoplastic
treatment modalities result in alteration of host natural
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defences, such as the occurrence of severe mucositis sec-
ondary to high-dose cytosine arabinoside therapy. Use
of central venous catheters may promote skin and soft-
tissue infections, as well as bacteremia [2]. Successful
control of initial infectious episodes of neutropenia and
fever may be followed by the emergence of secondary
episodes, and the knowledge of factors associated with
the risk for such events may be helpful for prevention
or treatment. Few studies have actually attempted to
identify such variables [3–5]. The aims of the present
study were to provide a description of etiologic and clin-
ical aspects of secondary episodes in febrile, neutropenic
patients with cancer who responded to an initial em-
pirical therapy and to identify factors associated with the
risk of a secondary episode.
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PATIENTS AND METHODS
The analysis was conducted on a dataset extracted from the
pooled database of 2 clinical trials of empirical antibiotic ther-
apy of febrile neutropenia in patients with hematological ma-
lignancies or with solid tumors performed by the International
Antimicrobial Therapy Group of the European Organization
for Research and Treatment of Cancer during the period of
1991–1994. The first study compared piperacillin-tazobactam
plus amikacin with ceftazidime plus amikacin [6], and the sec-
ond compared meropenem monotherapy with ceftazidime plus
amikacin [7]. To avoid bias related to a potential dependency
between outcome data, only first entries for each patient were
included. In addition, we selected only patients who responded
to the initial therapy for analysis, because information on this
outcome in nonresponding patients is often confused and un-
reliable. Fever was defined as a single temperature measurement
of 38.5C or 2 measurements of 38.0C within a 12-h
period. Neutropenia at enrollment in the trials was defined as
an absolute granulocyte count of !1000 cells/mm3 that was
anticipated to decrease to !500 cells/mm3 within 24–48 h [6–
8]. As in our standard definitions [6], a secondary infection
was defined as any episode of fever and/or infection not present
at the initial evaluation that developed either during empirical
therapy or within 1 week after discontinuation of therapy. In
the case of microbiologically documented infection, the isolated
pathogen should have been different from the pathogen isolated
during the primary episode. Primary infections were classified,
as in our standard definitions, as microbiologically documented
infections, clinically documented infections, and fever of un-
known origin. Secondary infections were classified as micro-
biologically documented infections (with or without blood-
stream infection [BSI]—that is, bacteria and/or fungi isolated
from samples of blood or from other sites), viral infections,
clinically documented infections (when a microbiological doc-
umentation was missing, but there were objective and detect-
able signs of infection), or fever of unknown origin. Micro-
biologically documented infections or clinically documented
infections were counted as “secondary” between day 0 and day
4, because the success of initial regimen, by definition, required
a minimum of 4 afebrile days.
For detection of possible associations between patients and/
or infection characteristics and the occurrence of a secondary
infection (yes vs. no), 2 groups of variables were considered:
those assessable on day 0 (day of enrollment in the trial), and
those assessable on day 4 after enrollment. Variables assessed
on day 0 were age, sex, underlying disease (acute leukemia,
first induction; acute leukemia in stages other than fist induc-
tion; and other), receipt of a bone marrow transplant (BMT;
autologous, allogeneic, or no BMT), presence of a localized
infection (in addition to fever), presence of an intravenous line,
severity of neutropenia (using the level 100 cells/mm3 as cutoff),
body temperature (using the temperature 39C as cutoff), ad-
ministration of oral antibacterial (quinolone with or without
penicillin, trimethoprim-sulfamethoxazole), antiviral (acyclo-
vir) or antifungal (nystatin, amphotericin B, ketoconazole, itra-
conazole, or fluconazole) prophylaxis before trial, decision to
continue the oral administration of these agents during em-
pirical therapy (depending on each participating center’s stan-
dard practice), use of granulocyte colony-stimulating factors,
and type of empirical antibiotic regimen as allocated at ran-
domization. Variables assessed on day 4 after enrollment in-
cluded severity of neutropenia, differential granulocyte count
between day 0 and day 4 (increasing, stable, or decreasing),
type of documentation of the primary episode (available and
recorded on day 4, based on tests performed at enrollment or
immediately after), and temperature on day 4.
Criteria were those used in previous trials from our group
[9, 10] or were based on the median distribution of the variable
to be categorized to make groups of comparable sizes. All cat-
egories are described in tables 1 and 2. Differential granulocyte
count between day 0 and day 4 was categorized as decreasing,
stable, or increasing. A stable count was defined as a relative
variation of !10% or as an absolute variation of !100 cells/
mm3. Temperature on day 4 was dichotomized as no fever or
persistent fever. Only covariates with !10% of missing data
were selected for the analysis. To make sure that we were not
missing important information by mixing documented and
nondocumented secondary episodes, we performed 2 analyses,
including and excluding fever of unknown origin from the list
of secondary episodes.
We first looked at the univariate association between the
outcome and each of the considered covariates using logistic
regression models. Estimated ORs were computed with 95%
CIs, and likelihood ratio tests were done to test the hypothesis
of an OR different from 1. Variables associated with a P value
of !.3 in univariate analysis were retained to be included in
the multivariate analysis to be conducted in a second step. The
final models were selected using a backward-stepwise method
(a P value of !.05 was necessary for the variable to remain in
the model). Time to secondary infection was estimated by the
Kaplan Meier method. Death rates at day 30 were compared
using the x2 test for heterogeneity. All reported P values are
2-tailed.
RESULTS
A total of 1971 febrile neutropenic episodes were included in
the 2 randomized trials. There were 1720 patients with eligible
first febrile episodes, and 836 (49%) responded to the initial
empirical treatment and therefore fulfilled our selection criteria.
Among patients selected in the present study, 63% had received
antibacterial prophylaxis, 57% had received antifungal pro-
phylaxis, and 23% had received antiviral prophylaxis. A sec-
Table 1. Characteristics of 836 patients and univariate analysis of baseline factors associated
with secondary infections.
Covariate
No. of
patients
Rate of
superinfection, % OR (95% CI) P
Age, years
16 192 7.3 1
116 644 17.9 2.76 (1.56–4.94) .001
Sex
Male 433 14.3 1
Female 403 16.6 1.19 (0.82–1.74) .36
Underlying disease
Acute leukemia, first induction 166 30.1 3.86 (2.46–6.07) !.001
Acute leukemia, other setting 222 15.3 1.62 (1.00–2.61) .05
Other 448 10.0 1
Bone marrow transplantation
No 646 16.1 1
Autologous 133 14.3 0.79 (0.50–1.27) .34
Allogeneic 56 10.7 …
Clinical site of infection
No 537 16.9 1
Yes 299 12.7 0.71 (0.47–1.07) .11
Intravenous line in situ
No 199 8.0 1
Yes 637 17.7 2.47 (1.42–4.27) .001
Granulocyte count, cells/mm3
!100 525 16.0 1
100 308 14.6 0.82 (0.53–1.28) .39
Temperature, C
!39 597 15.2 0.95 (0.63–1.44) .81
39 239 15.9 1
Oral antibacterial therapy before trial
No 313 11.8 1
Yes 523 17.6 1.59 (1.06–2.40) .03
Oral antifungal therapy before trial
No 362 11.0 1
Yes 474 18.8 1.86 (1.25–2.78) .002
Oral antiviral therapy before trial
No 646 16.3 1
Yes 190 12.6 0.75 (0.46–1.20) .23
Growth factors received during the
episode of neutropenia
No 556 16.2 1
Yes 278 13.7 0.82 (0.54–1.24) .34
Oral antibacterial therapy during trial
No 731 16.0 1
Yes 105 11.4 0.68 (0.36–1.28) .23
Oral antifungal therapy during trial
No 274 9.9 1
Yes 562 18.1 2.03 (1.29–3.19) .002
Oral antiviral therapy during trial
No 600 16.3 1
Yes 236 12.6 1.22 (0.82–1.84) .33
Empirical treatment
Ceftazidime and amikacin 407 16.7 1
Piperacillin-tazobactam and amikacin 159 14.5 0.84 (0.51–1.41) .51
Meropenem 270 14.1 0.82 (0.53–1.26) .36
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Table 2. Univariate analysis using variables assessable on day 4 after the
onset of fever.
Covariate assessed on day 4
No. of
patients
(n p 836) Rate, % OR (95% CI) P
Granulocyte count, cells/mm3 !.001
!100 408 23.0 3.47 (2.27–5.31)
100 416 7.9 1
Differential granulocyte count
Increasing 288 6.3 1
Stable 424 19.1 3.54 (2.07–6.05) !.001
Decreasing 110 25.5 5.12 (2.70–9.73) !.001
Infection documentation .004
CDI 225 9.3 1
Other 611 17.7 2.09 (1.27–3.42)
MDI 160 20.6 …
FUO 451 16.6 …
Fever .60
Noa 693 15.7 1
Persisting 143 14.0 0.87 (0.52–1.46)
NOTE. CDI, clinically documented infection; FUO, fever of unknown origin; MDI, microbi-
ologically documented infection.
a Temperature, !38C.
ondary infection occurred in 129 (15%) of 836 patients (95%
CI, 13%–18%). There were 40 microbiologically documented
infections, 14 with and 26 without BSI. In addition, there were
11 single-virus infections (9%; 8 herpes simplex virus infections
and 3 cytomegalovirus infections), 39 clinically documented
infections (30%), and 39 fevers of unknown origin (30%). Sites
of infection in patients with clinically documented infection
were the respiratory tract (including the oropharynx) in 23
patients, skin and soft tissue in 6 patients, the gastrointestinal
tract in 4 patients, the intravenous device insertion site in 4
patients, and other sites in the last 2 patients. The causes of
microbiologically documented infections are shown in table 3.
A total of 50 bacterial or fungal pathogens were isolated, in-
cluding those isolated in multibacterial and mixed infections.
Of them, 25 (50%) were gram-positive bacteria, 4 (8%) were
gram-negative rods, and 21 (42%) were fungi. One herpes sim-
plex virus infection occurred concurrently with a Candida al-
bicans infection and was classified as a mixed microbiologically
documented infection without BSI.
The cumulative risk of secondary infections, according to
the number of days after randomization, is presented in figure
1. The median time to development of secondary infection was
10 days (range, 1–28 days; interquartile range, 7–12 days). Only
8 of 129 secondary infections developed before day 5. The
overall crude mortality at day 30 was significantly higher among
patients with than among those without secondary infections
(7 [5.4%] of 129 vs. 10 [1.4%] of 707; OR, 4.00; 95% CI, 1.49–
10.71; ). When fevers of unknown origin were excludedPp .01
and only documented secondary infections were considered,
the median time to infection did not change significantly (9
days; interquartile range, 7–12 days).
Analysis of factors associated with the risk of secondary
infections. Table 1 presents the baseline characteristics of pa-
tients and the association of these characteristics with the risk
of secondary infection in a univariate model. Among baseline
factors, age of 116 years (OR, 2.76; ), acute leukemiaPp .001
treated with first-induction chemotherapy (OR, 3.86; ),P ! .001
acute leukemia in a stage other than first induction (OR, 1.62;
), presence of an intravenous line in situ (OR, 2.47;Pp .05
), receipt of antibacterial prophylaxis before enroll-Pp .001
ment (OR, 1.59; ), and receipt of antifungal prophylaxisPp .03
before enrollment (OR, 1.86; ) and during empiricalPp .002
therapy (OR, 2.03; ) were all associated with an in-Pp .002
creased risk of secondary infection. Among factors assessed on
day 4 after enrollment (table 2), the severity of neutropenia
(OR, 3.47; ), stable granulocyte count (OR, 3.54;P ! .001 P !
), decreasing granulocyte count (OR, 5.12; ), and.001 P ! .001
presence of a microbiologically documented infection or a fever
of unknown origin (associated with a clinically documented
infection) as documentation of the primary episode (OR, 2.09;
), were all associated with an increased risk of sec-Pp .004
ondary infection.
As shown in table 4, when the data were fit in a multivariate
logistic regression model on the basis of covariates assessable
at randomization, adult age (OR, 3.13; ), acute leukemiaP ! .001
in first induction (OR, 3.62; ), and presence of intra-P ! .001
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Table 3. Etiology of microbiologically documented secondary
infections (MDIs) in 40 patients.
Infection class, microorganism
No. of
patients
MDI with bloodstream infection 14
Single-bacterial infection
Staphylococcus haemolyticus 2
Bacillus species 1
Corynebacterium species 1
Enterococcus faecalis 1
Streptococcus viridans 1
Multibacterial infection
Clostridium species and Streptococcus viridans 2
Corynebacterium JK and E. faecalis 1
S. haemolyticus and Staphylococcus species 1
Fungal infection
Candida krusei 1
Candida tropicalis 1
Candida albicans and Candida glabrata 1
Mixed infection: Staphylococcus epidermidis
and C. glabrata 1
MDI without bloodstream infection 26
Single-bacterial infection
Coagulase-negative staphylococci 5
Staphylococcus aureus 2
Staphylococcus species 1
Clostridium difficile 1
Escherichia coli 1
Multibacterial infection: Pseudomonas aeruginosa
and Enterobacter species 1
Fungal infection
C. albicans 3
Candida species 2
Aspergillus species 3
Aspergillus fumigatus 1
Mucor species 1
C. albicans and C. glabrata 1
Pneumocystis carinii 1
Mixed infection 1
Aspergillus species and Clostridium species 1
Alternaria species and E. coli 1
C. albicans and herpes simplex virus 1
Figure 1. Time to development of a superinfection in 129 patients
venous line in situ (OR, 2.38; ) continued to havePp .003
independent predictive value. Two additional factors (absolute
granulocyte count on day 4 [OR, 2.72; ] and type ofP ! .001
documentation [clinically documented infection vs. other; OR,
2.56; ]) were found to also be associated with increasedPp .001
risk of secondary infections when the day 4 covariates were
included in the model.
Analysis of factors associated with the risk of documented
secondary infection. A multivariate analysis using only clin-
ically and microbiologically documented secondary infections
as dependent variables yielded similar results, with 2 differences:
the presence of an intravenous line at enrollment was no longer
statistically significant, whereas the administration of antiviral
prophylaxis became significantly protective (OR, 0.42; 95% CI,
0.22–0.79; ).Pp .007
DISCUSSION
The clinical problem of secondary fever and infection in neu-
tropenic patients with cancer has not been addressed very often
in the medical literature. Although there has been a reference
to the problem in several trials in which different antimicrobial
regimens were compared, the question was specifically exam-
ined in only a few studies, which reported variable rates, prob-
ably depending on different patient populations and different
definitions. In the present study, we found a rate of secondary
infections of 15% among patients who were successfully treated
with the empirical antibiotic treatment given at the time of
randomization in the trials. This rate compared well with the
one reported by Serra et al. [3], who found a rate of 12% (78
of 631 patients, with a total of 102 episodes). The only risk
factors that these authors found on univariate analysis were the
severity and persistence of granulocytopenia, which was as-
sessed as the duration of granulocytopenia before the devel-
opment of fever. There was no relationship between develop-
ment of secondary infection and length of hospitalization,
duration of previous antibiotic therapy, previous chemopro-
phylaxis, and presence of indwelling venous catheters. Feld et
al. [4] published their data only in an abstract form. With
respect to our findings, they reported a higher rate of secondary
infection, which they identified in 154 (24%) of 644 severely
febrile neutropenic patients who had acute leukemia or who
had undergone bone marrow transplantation. The multivariate
analysis indicated that longer duration of antimicrobial therapy
and lack of response to empirical therapy were both indepen-
dent factors for developing secondary infection, whereas an-
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Table 4. Findings of multivariate analyses of covariates at
baseline and on day 4 after onset of fever.
Covariate OR (95% CI) P
Baseline covariates only (np836)
Age, years
!16 1 !.001
16 3.13 (1.73–5.66)
Underlying malignancy
Acute leukemia
First induction 3.62 (2.28–5.76) !.001
Stage other than first induction 1.57 (0.96–2.56) .07
Other malignancy 1
Intravenous line
Not present 1
Present 2.38 (1.35–4.21) .003
With addition of day 4 covariates (np822)
Age, years
!16 1
16 3.46 (1.89–6.33) !.001
Underlying malignancy
Acute leukemia
First induction 3.17 (1.96–5.15) !.001
Stage other than first induction 1.34 (0.80–2.23) .26
Other malignancy 1
Intravenous line
Not present 1
Present 1.88 (1.02–3.48) .04
Granulocyte count on day 4, cells/mm3
!100 2.72 (1.72–4.28) !.001
100 1
CDI documented as cause of fever
on day 4 1
Cause of fever other than CDI 2.56 (1.51–4.36) .001
NOTE. CDI, clinically documented infection.
tiviral prophylaxis had a protective effect. Duration of neutro-
penia had no effect on the development of a secondary
infection. Nucci et al. [5] prospectively evaluated 46 additional
infectious episodes that developed in 333 febrile neutropenic
attacks (14%). They identified 4 independent factors by mul-
tivariate analysis that were related to an increased incidence of
secondary infections: longer duration of severe neutropenia
(absolute granulocyte count, !100 cells/mm3), lack of use of
prophylactic quinolones, persistence of fever on day 4 of the
initial regimen of empirical therapy, and presence of a central
venous catheter. The mortality rate was doubled among patients
with secondary infection.
In the present study, bacteria (mainly gram-positive bacteria)
accounted for 58% of the 50 bacterial and fungal pathogens
isolated from patients with documented infection. This was not
surprising, because 63% of our patients had received quinolone
or trimethoprim-sulfamethoxazole prophylaxis, which pro-
vided efficacy against gram-negative bacteria but not full effi-
cacy against gram-positive bacteria. Fungal pathogens were iso-
lated from 19 (48%) of 40 patients with secondary documented
infection, a rate lower than the rate of 67% reported by Nucci
et al. [5], although it is still relevant. The difference might be
explained by the fact that 57% of our patients had received
oral antifungal prophylaxis, and 67% had received these agents
while receiving empirical antimicrobial therapy, whereas only
17% of patients were given antifungal prophylaxis in the trial
by Nucci et al. [5]. This possible explanation, however, is par-
tially contradicted by the fact that, in our study, the predictive
effect of antifungal prophylaxis was statistically significant only
in univariate analysis but not in the final multivariate model.
Of the baseline factors, age of 116 years, acute leukemia as
an underlying disease, and presence of an intravenous line were
significantly associated with higher incidence of secondary ep-
isodes. These factors remained significant even when factors
available on day 4 were included in the model. Children have
always been shown to be at lower infection risk than adults,
probably because of differences in underlying diseases and a
better general performance status. This fact was also shown by
our group recently [11]. As is widely known, patients with acute
leukemia receive more-intensive chemotherapeutic regimens
than do other oncological patients, and this exposes these pa-
tients to a higher risk of infectious complications [12]. Un-
controlled underlying disease at admission and longer duration
of neutropenia (median, 23 days in patients with the first in-
duction of acute leukemia, vs. 19 days in patients with acute
leukemia with a stage other than first induction [ ], andPp .01
vs. 10 days in the remaining patients; data not shown) might
be responsible for more-frequent secondary infections in pa-
tients with the first induction of acute leukemia. Finally, in-
travenous catheters are a well-known source of infection, es-
pecially for gram-positive bacteria [2]. Because the initial
empirical regimens for febrile neutropenic patients usually do
not provide reliable coverage against most gram-positive agents,
and because they even may select for resistant pathogens during
therapy, it is not surprising that the patients with an intravenous
catheter in place would be more likely to develop superinfec-
tions during the course or after completion of the empirical
treatment regimen [13].
In the present analysis, the absolute granulocyte count at the
time of development of fever (i.e., enrollment in the trials) was
not predictive of the risk of secondary infection. On the con-
trary, patients who were persistently and severely granulocy-
topenic on day 4 were statistically more prone to develop sec-
ondary infections. These findings compared well with those
reported by Nucci et al. [5], although the same finding was not
reported by others [4]. Because persistent and severe neutro-
penia is a well-known predisposing factor for infection in feb-
rile, neutropenic patients with cancer [14], it could be an ex-
pected risk factor for secondary infections as well. The use of
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growth factors was not associated with the development of
secondary infections. However, we did not find any relationship
between underlying disease, severity of neutropenia, and use
of growth factors. At study entry, similar numbers of patients
in all 3 underlying disease categories had neutropenia (includ-
ing those with severe neutropenia, defined as a granulocyte
count of !100 cells/mm3). Furthermore, there was no difference
in the proportion of patients who received growth factors in
various categories of patients (data not shown).
Administration of antiviral prophylaxis was excluded from
the final model when all secondary infections (including fever
of unknown origin) were considered. However, interestingly, it
was shown to play a significant role when only documented
infections were evaluated. This issue has been addressed pre-
viously in the literature with conflicting results. Lonnqvist et
al. [15] reported that oral acyclovir prophylaxis may reduce the
rate of microbiologically documented infection in patients with
acute leukemia, whereas Bergmann et al. [16] more recently
noted that acyclovir prophylaxis postponed the development
of fever, but it did not have an effect on the duration of fever
or on the need for antibiotics and did not reduce the incidence
of bacteremia. It is possible that antiviral prophylaxis may
protect the integrity of oral mucosa by preventing herpetic
stomatitis.
Several prognostic factors influencing mortality have been
described in febrile, neutropenic patients with cancer [9–11,
17]. In accordance with previous reports [3, 5], the present
results confirm that development of a secondary infection is
a significant additional factor for increased mortality among
these patients.
In the present study, we analyzed secondary infections only
in patients who responded to the initial empirical regimen. This
means that our results cannot be applied to all febrile and
neutropenic patients. However, when considering confusion
regarding the discrimination between primary and secondary
or associated episodes in nonresponding patients, we believe
that this was the only way to address the problem with the
available data. Our study has been able to identify some clinical
parameters that, if present, might alert physicians to a possible
risk of new complications. Obviously, only ad hoc, prospective
epidemiological studies might be able to give more insight on
this problem.
Acknowledgments
Potential conflicts of interest. C.V. has received research grants and/
or served on the speaker’s bureaus for Wyeth Pharmaceuticals, Gilead
Sciences, Pfizer International, and Merck Sharp & Dohme. All other au-
thors: no conflicts.
References
1. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new?
Curr Opin Infect Dis 2002; 15:377–82.
2. Cordonnier C, Buzyn A, Leverger G, et al. Epidemiology and risk
factors for gram-positive coccal infections in neutropenia: toward a
more targeted antibiotic strategy. Clin Infect Dis 2003; 36:149–58.
3. Serra P, Santini C, Venditti M, Mandelli F, Martino P. Superinfections
during antimicrobial treatment with betalactam–aminoglycoside com-
binations in neutropenic patients with hematologic malignancies. In-
fection 1985; 13(Suppl 1):S115–22.
4. Feld R, Goodman PJ, Higgins B, et al. Prognostic factors for the de-
velopment of superinfections in febrile neutropenic cancer patients
[abstract 1695 ]. In: Program and abstracts of the 32th Interscience
Conference on Antimicrobial Agents and Chemotherapy (Anaheim).
Washington, DC: American Society for Microbiology, 1992:393.
5. Nucci M, Spector N, Bueno AP, et al. Risk factors and attributable
mortality associated with superinfections in neutropenic patients with
cancer. Clin Infect Dis 1997; 24:575–9.
6. Cometta A, Zinner S, De Bock R, et al. Piperacillin-tazobactam plus
amikacin versus ceftazidime plus amikacin as empiric therapy for fever
in granulocytopenic patients with cancer. Antimicrob Agents Che-
mother 1995; 39:445–52.
7. Cometta, A, Calandra T, Gaya H, et al. Monotherapy with meropenem
versus combination therapy with ceftazidime plus amikacin as empiric
therapy for fever in granulocytopenic patients with cancer. Antimicob
Agents Chemother 1996; 40:1108–15.
8. Hughes WT, Armstrong A, Bodey GP, et al. 2002 Guidelines for the
use of antimicrobial agents in neutropenic patients with cancer. Clin
Infect Dis 2002; 34:730–51.
9. Viscoli C, Bruzzi P, Castagnola E, et al. Factors associated with bac-
teraemia in febrile, granulocytopenic cancer patients. The International
Antimicrobial Therapy Cooperative Group (IATCG) of the European
Organization for Research and Treatment of Cancer (EORTC). Eur J
Cancer 1994; 30A:430–7.
10. Viscoli C, Paesmans M, Sanz M, et al. Association between antifungal
prophylaxis and rate of documented bacteremia in febrile neutropenic
cancer patients. Clin Infect Dis 2001; 32:1532–7.
11. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison
of outcome from febrile neutropenic episodes in children compared
with adults: results from four EORTC studies. International Antimi-
crobial Therapy Cooperative Group (IATCG) of the EORTC. Br J Hae-
matol 1997; 99:580–8.
12. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational
Association for Supportive Care in Cancer risk index: a multinational
scoring system for identifying low-risk febrile neutropenic cancer pa-
tients. J Clin Oncol 2000; 18:3038–51.
13. Schimpff SC, Scott DA, Wade JC. Infections in cancer patients: some
controversial issues. Support Care Cancer 1994; 2:94–104.
14. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships
between circulating leukocytes and infection in patients with acute
leukemia. Ann Intern Med 1966; 64:328–40.
15. Lonnqvist B, Palmblad J, Ljungman P, et al. Oral acyclovir as pro-
phylaxis for bacterial infections during induction therapy for acute
leukaemia in adults. The Leukemia Group of Middle Sweden. Support
Care Cancer 1993; 1:139–44.
16. Bergmann OJ, Mogensen SC, Ellermann-Eriksen S, Ellegaard J. Acy-
clovir prophylaxis and fever during remission-induction therapy of
patients with acute myeloid leukemia: a randomized, double-blind,
placebo-controlled trial. J Clin Oncol 1997; 15:2269–74.
17. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, et al. Prognostic
factors influencing mortality in cancer patients with neutropenia and
bacteremia. Eur J Clin Microbiol Infect Dis 1999; 18:539–44.
